MDxHealth (MDXH) Projected to Post Earnings on Wednesday

MDxHealth (NASDAQ:MDXH - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Wednesday, May 14th. Analysts expect MDxHealth to post earnings of ($0.13) per share and revenue of $22.62 million for the quarter.

MDxHealth (NASDAQ:MDXH - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.07. The firm had revenue of $24.74 million during the quarter, compared to analysts' expectations of $22.67 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. On average, analysts expect MDxHealth to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

MDxHealth Price Performance

NASDAQ MDXH remained flat at $1.72 during midday trading on Monday. 9,480 shares of the company's stock traded hands, compared to its average volume of 86,573. The stock has a fifty day moving average of $1.58 and a two-hundred day moving average of $1.86. MDxHealth has a 52 week low of $1.35 and a 52 week high of $3.50. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.45 and a current ratio of 1.54. The firm has a market cap of $81.34 million, a PE ratio of -1.13 and a beta of 1.29.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.